Overview
Founded in 2008 and listed on NASDAQ and Euronext Brussels, argenx is one of Belgium's most successful biotech companies by market capitalization. The company focuses on developing treatments for severe autoimmune diseases using its proprietary antibody technology platform, SIMPLE Antibody. Its lead product, efgartigimod, is approved in multiple markets for myasthenia gravis and several other indications.
Media & appearances
- De TijdYouTube28/07 | Politie zet burgerpersoneel volop in voor gevoelige taken | Niet alleen klimaatveranderin...Belgian-Dutch biotech acquiring US peer Forte Biosciences for $2.2 billion to diversify beyond blockbuster drug Vyvgart before its patent expires.
- De TijdYouTube23/07 | Brusselse beurs wordt minder populair | Alphabet klopt verwachtingen, Tesla onder de lat ...The other Belgian star stock still attracting trading interest, benefiting from ETF flows tied to the Euro Stoxx 50.
- De TijdYouTube20/07 | Weekvooruitblik met columnist Rik Van Cauwelaert | Politiek geladen 21 juli | Nieuwe Brit...Belgian biotech and Bel 20 heavyweight reporting Thursday morning, with its golden product Vyvgart.
- De TijdYouTubeBeursvoyeurs Zomer | Serge Mampaey (De Tijd): 'Jim Cramer bracht Wall Street naar de huiskamer'The one Brussels biotech that would appeal to Cramer, since he only tolerates absolute top biotech players.
- De TijdYouTubeSophie Stegen (Euronext Brussel): ‘Een ETF op de Bel20 zal er pas komen wanneer grote beleggers e...Bel20 pharma heavyweight and Euronext Brussels client; now also has mini options (10 shares) available.
- De TijdYouTubeAlexander Roose (Argenta): 'Ik zie vandaag mooie kansen in de sector van de voedingsingrediënten'One of Belgium's two big pharma names with a phenomenal track record, though less diversified and facing potential disruption from Chinese pharma research.
Stated facts & numbers
- Argenx pays $2.2 billion for Forte Biosciences, a US biotech with no drug on the market; its key asset FB-102 is still in early testing phase.De Tijd 2026-07-280:09:14
- Vyvgart has become a commercial machine generating billions of euros per year for Argenx.De Tijd 2026-07-280:10:45
- Alphabet and Tesla report earnings Wednesday, SAP Thursday, Volkswagen Friday, and Argenx Thursday morning; Sofina reports half-year results on 2 September.De Tijd 2026-07-200:12:54
- Euronext mini options require only 10 shares (versus 100 for standard contracts) and exist on ASML, Argenx, UCB and — exceptionally at 1 share — Lotus Bakeries.De Tijd 2026-06-240:41:09
Funding & milestones
1 events found for argenx · 2026
AcquisitionDetailsAmount not disclosed
Source not attached to this recordDeal record
Recorded history so far. Original currencies are preserved; amounts in different currencies are not added together. Debt, grants, acquisitions and listings are separate event types. Undated events appear last.
Key people
In the news
- A platelet count measures platelets – the blood cells that help stop bleeding – not the full impact of living with ITP. Fatigue, brain fog, anxiety, and uncertainty are everyday realities of living with immune thrombocytopenia (ITP) that numbers alone can’t capture. This #ITPAwarenessMonth, we’re looking beyond the data to shine a light on the parts of living with ITP that can’t be measured by a lab test. Explore our ITP clinical trials and learn more about how we're advancing research to better understand ITP:
- At argenx, scientific discovery starts with curiosity and co-creation. From our llama-derived antibody discovery platform to ever-expanding partnerships with academic researchers through our Immunology Innovation Program (IIP), we’re combining complementary expertise to translate groundbreaking science into medicines for people living with diseases where the need for treatment remains high. In a recent conversation with our partners at Scientific American Custom Media, our Chief Scientific Officer Peter Ulrichts
- Waarde wordt gecreëerd in teams ++ Organisaties worden doorgaans vanuit de top ontworpen. HR richt zich op leiderschap, processen en de individuele medewerkerservaring. Maar volgens Loes Bresseleers, Head of HR bij argenx, dreigt daardoor de plek waar het werk werkelijk gebeurt uit beeld te verdwijnen: het team. Bij argenx volgen multidisciplinaire teams de ontwikkeling van een geneesmiddel, van de eerste ontdekking tot bij de patiënt. Welke expertise daarvoor nodig is, ligt niet voor altijd vast. Wanneer het werk verandert,
- Sommige ondernemersverhalen tonen perfect wat er mogelijk wordt wanneer wetenschap, ondernemerschap, talent en ambitie elkaar vinden. argenx is zo’n verhaal: gespecialiseerd in antilichaamtherapieën tegen auto-immuunziekten en uitgegroeid tot “het meest waardevolle biotechbedrijf van Europa”. Maar hoe bouw je vanuit onze regio zo’n wereldspeler? Welke keuzes maak je onderweg? Hoe schaal je ambitie? En hoe blijf je vooruitkijken wanneer je bedrijf internationaal doorbreekt? Op 7 oktober horen we het van Tim Van Hauwermeiren op
- The questions that shape meaningful innovation often begin with patients, then advance through collaboration. At #CCRWest2026, argenx looks forward to connecting with clinical and academic experts who are advancing rheumatology research and deepening our understanding of immune-mediated disease. Through our Immunology Innovation Program (IIP), we bring together disease biology insights and our antibody engineering expertise to explore new possibilities and help translate promising science into meaningful impact for
- Meet the next keynote speaker of Science for health! We're excited to welcome Peter Ulrichts, Chief Scientific Officer at argenx, where he will give an opening keynote on: 🧬 "From Immunological Insight to Societal Impact: How Co-Creation Transforms Breakthrough Science into Better Lives" 🌱 argenx is a global immunology company translating breakthrough science into novel antibody-based medicines for severe autoimmune diseases, partnering with top academic researchers through its Immunology Innovation Program. It developed the
- Meet the next keynote speaker of Science for health! We're excited to welcome Peter Ulrichts, Chief Scientific Officer at argenx, where he will give an opening keynote on: 🧬 "From Immunological Insight to Societal Impact: How Co-Creation Transforms Breakthrough Science into Better Lives" 🌱 argenx is a global immunology company translating breakthrough science into novel antibody-based medicines for severe autoimmune diseases, partnering with top academic researchers through its Immunology Innovation Program. It developed the
- It’s easy to mistake what’s visible for the whole story. Autoimmune rheumatic diseases remind us there’s often more than meets the eye. For many people living with these conditions, the symptoms others can see are only one part of the challenges they navigate every day. This #RheumaticDiseaseAwarenessMonth, we're helping connect the invisible symptoms inside the body with their impact beyond what’s evident. #TogetherWeDiscover
Open roles (8)
- Associate Director, Statistical Modeling and SimulationGhent · Sep 10, 2026
- (Senior) Director, Strategic Alliances Enterprise Lead, ThermoFisher ScientificGhent · Sep 10, 2026
- (Senior) Director, Strategic Alliances Enterprise Lead, IQVIAWavre · Sep 10, 2026
- Project ToxicologistWavre · Sep 8, 2026
- Scientist Antibody CMC and DevelopabilityGhent · Sep 8, 2026
- Associate Director Ethics & ComplianceWavre · Sep 7, 2026
- Global DT Lead DevelopmentGhent · Sep 3, 2026
- Business Leader, Pacific & Northwest (Coastal CA)Sep 2, 2026
Alumni
Tim Van HauwermeirenChief Executive Officer
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.